New Drugs for Resistant Hypertension: Pending Issue?

Antihypertensive pharmacological treatment, based on currently available drugs, has been shown to reduce the cardiovascular risk profile of the treated hypertensive patients by lowering elevated blood pressure values. However, the risk of the treated hypertensive patients remains elevated. This represents the rationale for developing new antihypertensive drugs capable to normalize cardiovascular risk related to uncontrolled high blood pressure. This paper is designed at reviewing new antihypertensive drugs for the treatment of drug-resistant hypertension. The review will focus in particular on the results obtained with non-steroidal mineralcorticoid receptors antagonists, aldosterone synthase inhibitors, brain renin-angiotensin blockers, hepatic angiotensinogen inhibitors, atrial natriuretic peptides and endothelin 1 receptors antagonists.